Gastroenterology prior authorization at Florida Blue
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Florida Blue gastroenterology PA at a glance
Florida Blue reviews gastroenterology PA submissions against its medical policy library, with rules drawn primarily from AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target. Florida Blue-specific context: BCBS licensee for Florida (~5M members). Owned by GuideWell. Prime Therapeutics is the PBM (BCBS-aggregated PBM serving 19 BCBS plans). Florida OIR oversight. Largest ACA Marketplace participant in FL.
Documentation packet — what to send
- IBD diagnosis confirmed by endoscopy/biopsy
- Disease distribution and severity
- Prior conventional therapies tried
- Steroid course (drug, dose, taper attempts)
- Therapeutic drug monitoring labs where applicable
- Tuberculosis + hepatitis B screening prior to biologic
Common denial patterns to pre-empt
Patterns observed in gastroenterology across payers, and where Florida Blue's book of business overlaps:
- Step therapy through 5-ASA / immunomodulators / steroids first
- Switching between mechanism-of-action classes without documented failure
- Therapeutic drug monitoring not done before dose escalation
- Endoscopic disease not documented
- Step therapy via Prime Therapeutics PBM
Appeal angles when Florida Blue denies
- AGA / ACG guidelines for IBD positioning
- Endoscopic Mayo subscore or SES-CD documenting active disease
- Failure of prior biologic by mechanism of action (anti-TNF, anti-integrin, anti-IL-12/23, JAK)
- Steroid-dependence or steroid-refractory disease
Peer-to-peer prep
- Pull the most recent endoscopy report with photos if possible
- Quantify steroid dependence (mg of prednisone per year, taper attempts)
- Reference STRIDE-II treat-to-target if requesting mechanism switch
- Cite specific endoscopic scoring (Mayo, SES-CD) and the date
Drug-specific PA criteria at Florida Blue
Deep dives on each drug's PA criteria at Florida Blue:
Frequently asked questions
What documentation does Florida Blue need for gastroenterology prior authorizations?
Florida Blue's PA packet for gastroenterology typically includes: IBD diagnosis confirmed by endoscopy/biopsy; Disease distribution and severity; Prior conventional therapies tried; Steroid course (drug, dose, taper attempts). AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target citations strengthen the submission.
What's the turnaround at Florida Blue?
Florida Blue standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which gastroenterology drugs does Florida Blue most often PA-restrict?
Top targets in gastroenterology: adalimumab, infliximab, ustekinumab, risankizumab, tofacitinib. Each follows the per-drug step therapy + documentation requirements published in Florida Blue's medical policy library.
How do I prep a peer-to-peer with Florida Blue in gastroenterology?
Pull the most recent endoscopy report with photos if possible Quantify steroid dependence (mg of prednisone per year, taper attempts) Have the policy URL and the patient's chart open before the call.
Generate a Gastroenterology PA packet
Open ApprovalHelp — generate a gastroenterology PA packet tailored to Florida Blue's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com